US Patent

US11752190 — Modulators of complement activity

Method of Use · Assigned to Ra Pharmaceuticals Inc · Expires 2035-06-12 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using polypeptide modulators, including cyclic polypeptide modulators, as therapeutics.

USPTO Abstract

The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.

Drugs covered by this patent

zilucoplan-sodium (ZILUCOPLAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3735`	—	zilucoplan-sodium
`U-3735`	—	zilucoplan-sodium
`U-3735`	—	zilucoplan-sodium

Patent Metadata

Patent number: US11752190
Jurisdiction: US
Classification: Method of Use
Expires: 2035-06-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Ra Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.